{"id":69258,"date":"2026-07-02T15:30:25","date_gmt":"2026-07-02T07:30:25","guid":{"rendered":"https:\/\/flcube.com\/?p=69258"},"modified":"2026-07-02T15:30:26","modified_gmt":"2026-07-02T07:30:26","slug":"hangzhou-adamercks-aom0498-receives-nmpa-approval-as-chinas-first-homegrown-neuromuscular-blockade-reversal-agent-completing-decade-long-national-innovation-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69258","title":{"rendered":"Hangzhou Adamerck&#8217;s Aom0498 Receives NMPA Approval as China&#8217;s First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hangzhou Adamerck Pharmlabs Inc.<\/strong> announced that its independently developed <strong>Class 1 innovative drug Aom0498<\/strong> has received <strong>marketing approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, effective July 1, 2026. The new-generation <strong>specific neuromuscular blockade reversal agent<\/strong> represents China&#8217;s first domestically developed therapy in this critical perioperative category, completing a development journey supported by the <strong>National Major New Drug Creation and Development Program<\/strong> across three consecutive national planning periods.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>July 1, 2026<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Aom0498<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Class 1 innovative drug<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Reversal of residual neuromuscular blockade in general anesthesia surgery<\/td><\/tr><tr><td><strong>Development Support<\/strong><\/td><td>National Major New Drug Creation Program (&#8220;12th Five-Year Plan,&#8221; &#8220;13th Five-Year Plan,&#8221; &#8220;2020&#8221; periods)<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td>First Chinese-developed neuromuscular blockade reversal agent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-significance\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Significance<\/h2>\n\n\n\n<h3 id=\"h-aom0498-next-generation-reversal-agent\" class=\"wp-block-heading\">Aom0498 \u2013 Next-Generation Reversal Agent<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Category:<\/strong> Specific neuromuscular blockade reversal agent<\/li>\n\n\n\n<li><strong>Primary Benefits:<\/strong><\/li>\n\n\n\n<li>Facilitates early extubation in surgical patients<\/li>\n\n\n\n<li>Reduces postoperative complications from residual neuromuscular blockade<\/li>\n\n\n\n<li>Enables safer, more precise, and more complete reversal<\/li>\n\n\n\n<li><strong>Clinical Impact:<\/strong> Addresses critical unmet need in perioperative safety and recovery optimization<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> Represents breakthrough in Chinese pharmaceutical innovation for anesthesia support<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-development-heritage\" class=\"wp-block-heading\">Development Heritage<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>National Strategic Support:<\/strong> Backed by China&#8217;s premier drug innovation initiative across 10+ years<\/li>\n\n\n\n<li><strong>Domestic Achievement:<\/strong> Eliminates reliance on imported reversal agents in Chinese healthcare system<\/li>\n\n\n\n<li><strong>Technology Sovereignty:<\/strong> Demonstrates China&#8217;s capability to develop complex perioperative therapeutics independently<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-healthcare-impact\" class=\"wp-block-heading\">Market Opportunity &amp; Healthcare Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Surgical Volume:<\/strong> Over 60 million general anesthesia procedures annually in China create massive addressable market<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Limited options for complete neuromuscular blockade reversal, leading to residual complications<\/li>\n\n\n\n<li><strong>Clinical Burden:<\/strong> Residual neuromuscular blockade affects 30-40% of surgical patients, contributing to respiratory complications and extended recovery<\/li>\n\n\n\n<li><strong>Healthcare Economics:<\/strong> Early extubation reduces ICU stays and overall hospital costs by an estimated \u00a52,000-5,000 per patient<\/li>\n\n\n\n<li><strong>Reimbursement Priority:<\/strong> High likelihood of rapid inclusion in hospital formularies and provincial reimbursement lists<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Sole domestic supplier in \u00a52-3 billion Chinese neuromuscular reversal market<\/li>\n\n\n\n<li><strong>Export Potential:<\/strong> Quality certification supports potential expansion to other emerging markets<\/li>\n\n\n\n<li><strong>Portfolio Foundation:<\/strong> Establishes Hangzhou Adamerck as leader in perioperative therapeutics development<\/li>\n\n\n\n<li><strong>National Recognition:<\/strong> Success validates China&#8217;s decade-long investment in indigenous pharmaceutical innovation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market adoption and commercial performance. Actual results may differ due to risks including hospital procurement decisions, competitive dynamics, pricing pressures, and healthcare policy changes affecting perioperative pharmaceuticals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69259,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[4607,15],"class_list":["post-69258","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adamerck-pharmlabs","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hangzhou Adamerck&#039;s Aom0498 Receives NMPA Approval as China&#039;s First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China&#039;s National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China&#039;s first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National Major New Drug Creation and Development Program across three consecutive national planning periods.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69258\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hangzhou Adamerck&#039;s Aom0498 Receives NMPA Approval as China&#039;s First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China&#039;s National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China&#039;s first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National Major New Drug Creation and Development Program across three consecutive national planning periods.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69258\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-02T07:30:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-02T07:30:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hangzhou Adamerck&#8217;s Aom0498 Receives NMPA Approval as China&#8217;s First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program\",\"datePublished\":\"2026-07-02T07:30:25+00:00\",\"dateModified\":\"2026-07-02T07:30:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258\"},\"wordCount\":404,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0202.webp\",\"keywords\":[\"Adamerck Pharmlabs\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69258#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69258\",\"name\":\"Hangzhou Adamerck's Aom0498 Receives NMPA Approval as China's First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0202.webp\",\"datePublished\":\"2026-07-02T07:30:25+00:00\",\"dateModified\":\"2026-07-02T07:30:26+00:00\",\"description\":\"Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China's National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China's first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National Major New Drug Creation and Development Program across three consecutive national planning periods.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69258\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0202.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hangzhou Adamerck's Aom0498 Receives NMPA Approval as China's First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69258#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hangzhou Adamerck&#8217;s Aom0498 Receives NMPA Approval as China&#8217;s First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hangzhou Adamerck's Aom0498 Receives NMPA Approval as China's First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China's National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China's first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National Major New Drug Creation and Development Program across three consecutive national planning periods.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69258","og_locale":"en_US","og_type":"article","og_title":"Hangzhou Adamerck's Aom0498 Receives NMPA Approval as China's First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program","og_description":"Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China's National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China's first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National Major New Drug Creation and Development Program across three consecutive national planning periods.","og_url":"https:\/\/flcube.com\/?p=69258","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-02T07:30:25+00:00","article_modified_time":"2026-07-02T07:30:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69258#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69258"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hangzhou Adamerck&#8217;s Aom0498 Receives NMPA Approval as China&#8217;s First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program","datePublished":"2026-07-02T07:30:25+00:00","dateModified":"2026-07-02T07:30:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69258"},"wordCount":404,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69258#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0202.webp","keywords":["Adamerck Pharmlabs","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69258#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69258","url":"https:\/\/flcube.com\/?p=69258","name":"Hangzhou Adamerck's Aom0498 Receives NMPA Approval as China's First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69258#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69258#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0202.webp","datePublished":"2026-07-02T07:30:25+00:00","dateModified":"2026-07-02T07:30:26+00:00","description":"Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China's National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China's first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National Major New Drug Creation and Development Program across three consecutive national planning periods.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69258#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69258"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69258#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0202.webp","width":1080,"height":608,"caption":"Hangzhou Adamerck's Aom0498 Receives NMPA Approval as China's First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69258#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hangzhou Adamerck&#8217;s Aom0498 Receives NMPA Approval as China&#8217;s First Homegrown Neuromuscular Blockade Reversal Agent \u2013 Completing Decade-Long National Innovation Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69258"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69258\/revisions"}],"predecessor-version":[{"id":69260,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69258\/revisions\/69260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69259"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}